In an interview with Targeted Oncology, Filippo Pietrantonio, MD, discusses the safety and toxicity management of amivantamab (Rybrevant) plus chemotherapy for patients with metastatic colorectal cancer. As reported in updated data from the phase 1b/2 OrigAMI-1 study (NCT05379595), the overall safety profile of the combination is manageable and mirrors the experiences clinicians already have when using first-generation EGFR inhibitors combined with chemotherapy. Specifically, the rate of skin toxicity observed with this combination is in line with the rates seen for standard treatments like cetuximab (Erbitux) or panitumumab (Vectibix). A key finding is that the addition of amivantamab does not result in an apparent increase in chemotherapy-related toxicities, particularly hematological adverse events (AEs). Dr Pietrantonio notes that these are manageable through proactive monitoring.